Ligand Modification Research Articles

To Explore Potential Inhibitors Against Various Enzymatic Targets of Human African Trypanosomiasis.

Synthetic drugs currently prescribed for the treatment of Human African Trypanosomiasis (HAT) are non-specific, toxic, demand extended therapeutic regimes and are of varying efficacy. Along with the challenging demographic and socio-economic hurdles, the everincreasing risk of drug resistance is another major problem to be addressed. Cysteine protease, Heat shock proteins (HSP-90), Trypanothione reductase (TR), Farnesyl diphosphate synthase, Glucose-6-phosphate dehydrogenase, UP-4-galactose epimerase, and Cytidine triphosphate synthetase are potential enzymatic targets for the development of novel inhibitors against HAT which are the main focus of this review. The potential enzymatic targets of Trypanosoma brucei, especially small molecules like cysteine proteases and heat shock proteins are identified as major candidates for the sustenance of the parasite, their proliferation, infection, and spread of the disease. The development of new compounds to combat the disease by thorough ligand modification has been explored in the current review. Extracting these compounds and studying their efficacy, toxicity, and target mechanism extensively, this review has proposed a list of different compounds, including some synthetic and natural compounds along with multi-target inhibitors such as acoziborole, fexinidazole, etc. Potential inhibitors against these enzymatic targets of the T. brucei are important candidates for designing novel therapeutics against HAT. Multi-target inhibitors have also been identified as crucial molecules because of their potential advantage against the development of drug resistance.

Ligand modulation of active center to promote lead-free Cs2AgInCl6 photocatalytic CO2 reduction

Metal halide perovskites (MHP) are potential candidates for the photocatalytic reduction of CO2 due to their long photogenerated carrier lifetime and charge diffusion length. However, the conventional long-chain ligand impedes the adsorption and activation of CO2 molecules in practical applications. Here, a ligand modulation technology is employed to enhance the photocatalytic CO2 reduction activity of lead-free Cs2AgInCl6 microcrystals (MCs). The Cs2AgInCl6 MCs passivated by Oleic acid (OLA) and Octanoic acid (OCA) are used for photocatalytic CO2 reduction. The results show that the surface defects and electronic properties of Cs2AgInCl6 MCs can be adjusted through ligand modulation. Compared with the OLA-Cs2AgInCl6, the OCA-Cs2AgInCl6 catalyst demonstrated a significant improvement in the catalytic yield of CO and CH4. The CO and CH4 catalytic yields of OCA-Cs2AgInCl6 reached 171.88 and 34.15 µmol g−1 h−1 which were 2.03 and 12.98 times higher than those of OLA- Cs2AgInCl6, and the total electron consumption rate of OCA-Cs2AgInCl6 was 615.2 µmol g−1 h−1 which was 3.25 times higher than that of OLA-Cs2AgInCl6. Furthermore, in situ diffuse reflectance infrared Fourier transform spectra revealed the enhancement of photocatalytic activity in Cs2AgInCl6 MCs induced by ligand modulation. This study illustrates the potential of lead-free Cs2AgInCl6 MCs for efficient photocatalytic CO2 reduction and provides a ligand modulation strategy for the active promotion of MHP photocatalysts.

Modification of structure, epitope and allergenicity on heat-stressed ovalbumin by resveratrol

Allergen modification is a novel strategy for preventing and treating food allergy. Resveratrol (RES) can be used as a modifying ligand for allergens, but the interaction mechanism between RES and allergens is still not detailed, and the ramifications of this interaction on the structure, epitope and allergenicity of allergens are also lacking a clear explanation. In addition, the application of heat can promote protein structure to unfold and expose more binding sites to facilitate interaction. Therefore, in this study, ovalbumin (OVA) was selected as the allergen model and was heated to expose more binding sites. The effects of the interaction between RES and heat-stressed ovalbumin (HOVA) on allergen structure, epitope and allergenicity were investigated by combining routine experimental analysis and computer simulation. Results showed heat stress at 323 K for 15 min could better unfold the molecular structure of OVA. On this basis, the interaction between RES and OVA was strengthened, which showed a static quenching of the ground state complex with binding affinity of 1.25 × 106 L/mol. The binding of RES induced the variation of protein microenvironment, and the overall structure tended to disordered direction. Computer simulation had shown RES could directly act on the IgE epitope region (AA251-260) of the OVA. The allergenicity evaluation experiment further indicated the combination of RES alleviated the IgE binding capacity of HOVA. These findings are helpful to further study the mechanism of RES ligand modification to change food allergy.

Cu-phen Coordination Enabled Selective Electrocatalytic Reduction of CO2 to Methane.

Manipulation of selectivity in the catalytic electrochemical carbon dioxide reduction reaction (eCO2RR) poses significant challenges due to inevitable structure reconstruction. One approach is to develop effective strategies for controlling reaction pathways to gain a deeper understanding of mechanisms in robust CO2RR systems. In this work, by precise introduction of 1,10-phenanthroline as a bidentate ligand modulator, the electronic property of the copper site was effectively regulated, thereby directing selectivity switch. By modification of [Cu3(btec)(OH)2]n, the use of [Cu2(btec)(phen)2]n·(H2O)n achieved the selectivity switch from ethylene (faradaic efficiency (FE) = 41%, FEC2+ = 67%) to methane (FECH4 = 69%). Various in situ spectroscopic characterizations revealed that [Cu2(btec)(phen)2]n·(H2O)n promoted the hydrogenation of *CO intermediates, leading to methane generation instead of dimerization to form C2+ products. Acting as a delocalized π-conjugation scaffold, 1,10-phenanthroline in [Cu2(btec)(phen)2]n·(H2O)n helps stabilize Cuδ+. This work presents a novel approach to regulate the coordination environment of active sites with the aim of selectively modulating the CO2RR.

A hybrid steric ligand modification strategy promotes propylene (co)polymerization

Recently, a Hybrid Steric Ligand Modification (HSLM) strategy has been shown to significantly increase the polymerization activity and the branching degree of the resulting (co)polymers in the ethylene (co)polymerization via α-diimine catalysts. In this study, the HSLM strategy was employed for propylene (co)polymerization using a group of α-diimine Pd(II) catalysts with bulky hybrid ligands. The HSLM catalysts (Pd1-4) produced polypropylene with high molecular weights (45.4–156.9 kg/mol) and resulted in significantly high levels of activity (105 g mol−1 h−1). Additionally, nearly half of the propylene underwent chain straightening (1,3-enchainment = 43–46 %). Our findings suggest that Pd1-4 catalysts are more effective than the symmetrical catalysts Pd5-6 in producing high molecular weight polypropylene with high activity. Among all the catalysts tested, Pd4 with 4-tert-butylphenyl displayed the highest polymerization activity and molecular weight, although with lowest branching densities. It is suggested that the HSLM may provide a more open spatial configuration around the metal center, which facilitates the coordination and insertion of propylene molecules as well as chain walking. The hybrid Pd(II) catalysts showed moderate activity during the copolymerization of propylene with MA. The copolymers produced had low molecular weights (3.1–11.2 kg/mol), high branching densities (120–211/1000C), and high incorporation ratios (8.82–18.08 mol%). The copolymerization activity was highest with 4-tert-butylphenyl Pd4. The resulting P-MA copolymers had the highest molecular weight, the largest branching degree, and the lowest incorporation ratios.

Abstract CT101: Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumors

Abstract Background Dysregulated Wnt signalling drives several cancers through effects on proliferation, fibrosis and immune evasion. RXC004 is a novel oral small molecule inhibitor of protein-serine O-palmitoyltransferase (PORCN), which is required for the post-translational modification and activation of Wnt ligands. RXC004 has potential for efficacy in upstream Wnt pathway activated tumours: ~5% pancreatic cancer and ~8% microsatellite stable colorectal (CRC) cancer with RNF43 mutations or RSPO fusions, and tumors with high Wnt ligand expression. Methods In this Phase I study of RXC004 (NCT03447470), Module 1 investigated continuous monotherapy dosing, Module 2 investigated combination with nivolumab 480mg s.c. Q4W and Module 3 investigated intermittent monotherapy dosing (2 weeks on 1 week off). Patients received denosumab 120 mg s.c Q4W to prevent loss of bone mineral density (BMD), a known effect of Wnt inhibition. The primary objectives were safety and tolerability. Secondary objectives were PK and RECIST response. PD markers included on-treatment changes in: Wnt pathway and fibrosis biomarkers in paired skin biopsies; circulating immune subsets by flow cytometry; cytokine changes by Luminex, and changes in circulating-tumor DNA (ctDNA) levels by ddPCR. Results In Module 1, 25 patients (pts) with unselected advanced solid tumors (AST) received RXC004 between 0.5mg and 10mg QD. The RP2D was 2mg QD; at this dose the most common AEs were fatigue, diarrhoea, dysgeusia and decreased appetite; no grade 4/5 AEs or bone fragility events were reported whilst 1 pt had a RXC004-related grade 3 AE, 3 pts (50%) had a dose interruption and 1 had a dose reduction. The median T1/2 of RXC004 was 14.5h. 5 pts with upstream Wnt pathway activated tumors had stable disease (SD), in 1 case for 26 weeks with sustained reduction in ctDNA and no BMD loss. In Module 2, 14 patients with unselected AST received RXC004 at 1mg QD or 1.5mg QD with nivolumab. The AE profile was similar to Module 1. The RP2D was 1.5mg QD; at this dose 3 pts had a RXC004-related grade 3 AE, 6 pts (75%) had a dose interruption and 3 had a dose reduction, and 4 pts had SD. PK was similar to Module 1. In Module 3, 7 patients with upstream Wnt-activated AST received RXC004 2mg QD, 2 weeks on, 1 week off. The AE profile was similar to Modules 1 and 2. There were no RXC004-related Grade 3 AEs, 2 pts (29%) had a dose interruption and there were no dose reductions. PK and PD analyses confirmed time off target. 2 pts had SD; 1 pt with RSPO fusion small intestinal adenocarcinoma remained on treatment for 36 weeks, with sustained reduction in ctDNA and no BMD loss. Conclusions In patients with AST, RXC004 was safe and tolerated at doses up to 2mg QD as monotherapy and 1.5mg QD in combination with nivolumab, demonstrating differential disease control in upstream Wnt pathway activated tumours. Denosumab prevented loss of BMD. Intermittent RXC004 dosing was well tolerated with no detrimental impact on efficacy. Citation Format: Natalie Cook, Sarah Blagden, Juanita Lopez, Debashis Sarker, Alastair Greystoke, Noor MD Haris, Farasat Kazmi, Kaiser Anam, Ana Ortego Franco, Rille Pihlak, Louise Goodwin, David Wilson, Caroline Phillips, Jane Robertson, Helen Timmis, Craig Tilston, Simon A. Woodcock, Ruth Plummer. Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT101.

Improvement of the enantioselectivities of Mandyphos‐Pd complexes by introducing groups with different steric and electronic properties

AbstractBACKGROUNDMandyphos‐Pd has been proven to be a good chiral extractant to enantioseparate 3‐chlorophenylglycine enantiomers with a separation factor of 2.64. However, this extractant is not suitable to enantioseparate other amino acids with separation factors of <2.0. The poor versatility has limited its practical application in chiral extraction.RESULTSMandyphos derivatives with different steric and electronic properties were synthesized and their enantioseparation properties toward amino acid and mandelic acid enantiomers were investigated. The results suggested that substituent groups with different steric properties affect the extraction properties, probably by adjusting the angles of tetra‐coordinated palladium complexes. And the substituent groups with different electronic properties affect the extraction properties mainly by adjusting the π‐π interactions/steric hindrance effects between Mandyphos‐Pd and substrates. After optimization, the highest separation factors for phenylalanine, homophenylalanine, 3‐chloro‐phenylglycine, 4‐nitro‐phenylalanine, mandelic acid and 2‐Cl‐mandelic acid were 2.10, 2.77, 3.51, 2.42, 2.24 and 5.19, respectively. The enantioseparation mechanisms revealed that the coordination interactions between metal ions and COO−/NH2, π‐π interactions or steric hindrance effects between aryls are the main forces acting in chiral recognition.CONCLUSIONThe enantioselectivities of the Mandyphos‐Pd complex are improved by introducing groups with suitable steric and electronic properties. Structural modification is a useful method to improve the enantioseparation efficiencies of chiral extractants. The results of this work will supply important theoretical guidance and reference for the design and modification of novel diphosphine ligands in future work. © 2024 Society of Chemical Industry (SCI).

Evaluation of New Folate Receptor-mediated Mitoxantrone Targeting Liposomes In Vitro.

<p>Background: Ligand-mediated liposomes targeting folate receptors (FRs) that are overexpressed on the surface of tumor cells may improve drug delivery. However, the properties of liposomes also affect cellular uptake and drug release. <p> Objective: Mitoxantrone folate targeted liposomes were prepared to increase the enrichment of drugs in tumor cells and improve the therapeutic index of drugs by changing the route of drug administration. <p> Methods: Liposomes were prepared with optimized formulation, including mitoxantrone folatetargeted small unilamellar liposome (MIT-FSL), mitoxantrone folate-free small unilamellar liposome (MIT-SL), mitoxantrone folate-targeted large unilamellar liposome (MIT-FLL), mitoxantrone folate-free large unilamellar liposomes (MIT-LL). Cells with different levels of folate alpha receptor (FRα) expression were used to study the differences in the enrichment of liposomes, the killing effect on tumor cells, and their ability to overcome multidrug resistance. <p> The results of the drug release experiment showed that the particle size of liposomes affected their release behavior. Large single-compartment liposomes could hardly be effectively released, while small single-compartment liposomes could be effectively released, MIT-FSL vs MIT-FLL and MIT-SL vs MIT-LL had significant differences in the drug release rate (P<0.0005). Cell uptake experiments results indicated that the ability of liposomes to enter folic acid receptor-expressing tumor cells could be improved after modification of folic acid ligands on the surface of liposomes and it was related to the expression of folate receptors on the cell surface. There were significant differences in cell uptake rates (p<0.0005) for cells with high FRα expression (SPC-A-1 cells), when MIT-FSL vs MIT-SL and MIT-FLL vs MIT-LL. For cells with low FRα expression (MCF-7 cells), their cell uptake rates were still different (p<0.05), but less pronounced than in SPC-A-1 cells. The results of the cell inhibition experiment suggest that MIT-FLL and MIT-LL had no inhibitory effect on cells, MIT-FSL had a significant inhibitory effect on cells and its IC50 value was calculated to be 4502.4 ng/mL, MIT-SL also had an inhibitory effect, and its IC50 value was 25092.1 ng/mL, there was a statistical difference (p<0.05), MIT-FSL had a higher inhibitory rate than MIT-SL at the same drug concentration. Afterward, we did an inhibitory experiment of different MIT-loaded nanoparticles on MCF-7 cells compared to the drug-resistant cells (ADR), Observing the cell growth inhibition curve, both MIT-FSL and MIT-SL can inhibit the growth of MCF-7 and MCF-7/ADR cells. For MCF- 7 cells, at the same concentration, there is little difference between the inhibition rate of MITFSL and MIT-SL, but for MCF-7/ADR, the inhibition rate of MIT-FSL was significantly higher than that of MIT-SL at the same concentration (P<0.05). <p> Conclusion: By modifying folic acid on the surface of liposomes, tumor cells with high expression of folic acid receptors can be effectively targeted, thereby increasing the enrichment of intracellular drugs and improving efficacy. It can also change the delivery pathway, increase the amount of drug entering resistant tumor cells, and overcome resistance.</p>.

Optimizing ZnO–Quantum Dot Interface with Thiol as Ligand Modification for High‐Performance Quantum Dot Light‐Emitting Diodes (Small 13/2024)

Optimizing ZnO–Quantum Dot Interface with Thiol as Ligand Modification for High‐Performance Quantum Dot Light‐Emitting Diodes (Small 13/2024)

Impact of the Methylene Bridge Substitution in Chelating NHC-Phosphine Mn(I) Catalyst for Ketone Hydrogenation.

Systematic modification of the chelating NHC-phosphine ligand (NHC = N-heterocyclic carbene) in highly efficient ketone hydrogenation Mn(I) catalyst fac-[(Ph2 PCH2 NHC)Mn(CO)3 Br] has been performed and the catalytic activity of the resulting complexes was evaluated using acetophenone as a benchmark substrate. While the variation of phosphine and NHC moieties led to inferior results than for a parent system, the incorporation of a phenyl substituent into the ligand methylene bridge improved catalytic performance by ca. 3 times providing maximal TON values in the range of 15000-20000. Mechanistic investigation combining experimental and computational studies allowed to rationalize this beneficial effect as an enhanced stabilization of reaction intermediates including anionic hydride species fac-[(Ph2 PC(Ph)NHC)Mn(CO)3 H]- playing a crucial role in the hydrogenation process. These results highlight the interest of such carbon bridge substitution strategy being rarely employed in the design of chemically non-innocent ligands.

A multifunctional Eu-MOF with multi-color and proton conduction switching and its anti-counterfeiting applications

Lanthanide metal-organic frameworks (Ln-MOFs) have exhibited remarkable capabilities in color change, luminescence, proton conduction through the strategic modification of metal nodes, organic ligands and channels or pores. By modifying the electron-deficient bipyridinium to contain carboxylic acid moieties and coordinating them with the luninescent Eu3+ ion, a unique and versatile Eu-MOF has been synthesized. Under UV light conditions, the complex shows an obvious color change from colorless to blue, which is due to the formation of viologen radicals after photoinduced electron transfer (PIET) process. As we all know, the changed color is caused by the alteration of absorption intensity, ultimately impacting its luminescence as well. Thus, the bright and strong red fluorescence of this complex is quenched upon continuous UV light irradiation, which may be attributed to intramolecular energy transfer from the excited state of the europium ion to the colored state of the CV ligand. Based on the control of multiple colors of the complex, the designed encryption model can realize multiple anti-counterfeiting of real numbers. In addition, the conductivity of this compound increases significantly after UV illumination, showing excellent photo-modulated proton conductivity. In short, our work has proposed a multifunctional bipyridinium-based Ln-MOF with photochromism, photo-switchable photoluminescence and proton conduction, which offers valuable insights for the creation of versatile switchable materials based on MOFs.

Engineered PDGFA-ligand-modified exosomes delivery T3 for demyelinating disease targeted therapy

Demyelination is a proper syndrome in plenty of central nervous system (CNS) diseases, which is the main obstacle to recovery and still lacks an effective treatment. To overcome the limitations of the brain-blood barrier on drug permeability, we modified an exosome secreted by neural stem cells (NSCs), which had transfected with lentivirus armed with platelet-derived growth factors A (PDGFA)-ligand. Through the in vivo and in vitro exosomes targeting test, the migration ability to the lesion areas and OPCs significantly improved after ligand modification. Furthermore, the targeted exosomes loaded with 3,5, 30-L-triiodothyronine (T3) have a critical myelination ability in CNS development, administrated to the cuprizone animal model treatment. The data shows that the novel drug vector loaded with T3 significantly promotes remyelination compared with T3 alone. At the same time, it improved the CNS microenvironment by reducing astrogliosis, inhibiting pro-inflammatory microglia, and alleviating axon damage. This investigation provides a straightforward strategy to produce a targeting exosome and indicates a possible therapeutic manner for demyelinating disease.

Exploiting Orthogonal C-C Cross-Coupling Reactions for Chemistry-on-the-Complex: Modular Assembly of 2,6-Di(quinolin-8-yl)pyridine Ruthenium(II) Photosensitizer Triads.

In this work, we present a concise modular assembly strategy using one universal heteroleptic 2,6-di(quinolin-8-yl)pyridine-based ruthenium(II) complex as a starting building block. Extending the concept from established ligand modifications and subsequent complexation (classical route), the later appearing chemistry-on-the-complex methodology was used for late-stage syntheses, i.e., assembling discrete building blocks to molecular architectures (here: dyad and triads). We focused on Suzuki-Miyaura and Sonogashira cross-couplings as two of the best-known C-C bond forming reactions. Both were performed on one building block complex bearing a bromine and TIPS-protected alkyne for functional group interconversion (bromine to TMS-protected alkyne, a benzyl azide, or a boronic acid pinacol ester moiety with ≥95% isolated yield and simple purification) as well as building block assemblies using both a triarylamine-based donor and a naphthalene diimide-based acceptor in up to 86% isolated yield. Additionally, the developed purification via automated flash chromatography is simple compared to tedious manual chromatography for ruthenium(II)-based substrates in the classical route. Based on the preliminary characterization by steady-state spectroscopy, the observed emission quenching in the triad (55%) serves as an entry to rationally optimize the modular units via chemistry-on-the-complex to elucidate energy and electron transfer.

Structural insights into ligand modulation of TRPV2

Structural insights into ligand modulation of TRPV2

Ligand-Controlled Regiodivergent Nickel-Catalyzed Hydroaminoalkylation of Unactivated Alkenes.

Ligand modulation of transition-metal catalysts to achieve optimal reactivity and selectivity in alkene hydrofunctionalization is a fundamental challenge in synthetic organic chemistry. Hydroaminoalkylation, an atom-economical approach for alkylating amines using alkenes, is particularly significant for amine synthesis in the pharmaceutical, agrochemical, and fine chemical industries. However, the existing methods usually require specific substrate combinations to achieve precise regio- and stereoselectivity, which limits their practical utility. Protocols allowing for regiodivergent hydroaminoalkylation from the same starting materials, controlling both regiochemical and stereochemical outcomes, are currently absent. Herein, we report a ligand-controlled, regiodivergent nickel-catalyzed hydroaminoalkylation of unactivated alkenes with N-sulfonyl amines. The reaction initiates with amine dehydrogenation and involves aza-nickelacycle intermediates. Tritert-butylphosphine promotes branched regioselectivity and syn diastereoselectivity, whereas ethyldiphenylphosphine enables linear selectivity, yielding regioisomers with inverse orientation. Systematic evaluation of diverse monodentate phosphine ligands reveals distinct regioselectivity cliffs, and % Vbur (min), a ligand steric descriptor, was established as a predictive parameter correlating ligand structure to regioselectivity. Computational investigations supported experimental findings, offering mechanistic insights into the origins of regioselectivity. Our method provides an efficient and predictable route for amine synthesis, demonstrating broad substrate scope, excellent tolerance toward various functional groups, and practical advantages. These include the use of readily available starting materials and cost-effective nickel(II) salts as precatalysts.

Enhancement of nanozyme activity by second ligand modification on glutathione protected gold nanoclusters for regulation of intracellular oxidative stress

Nanozymes, as an alternative to natural enzymes, have received wide interests in recent years. Here, we have separated two main glutathione protected gold nanoclusters (GSH-Au NCs), namely, high fluorescent species with low peroxidase-like activity, and low fluorescent species with high peroxidase-like activity, from NCs prepared using different ratios of precursors. Additionally, the peroxidase-like activity of the latter species can be regulated by surface modification of a second thiolate ligand. As a representative, L-cysteine (L-Cys) modified GSH-Au NCs may exhibit both enhanced peroxidase-like activity (up to 5-fold) and improved fluorescent properties (∼3.3-fold) compared with GSH-Au NCs. The cytotoxicity and reactive oxygen species (ROS) level detection demonstrate that L-Cys modified NCs may cause effective cytotoxicity on breast cancer cells through the selective ROS generation. This study further expands the peroxidase-like kinetics of surface modified Au NCs and provides a new possibility for regulating the level of oxidative stress in cells.

Synergetic Effect of Ligand Modification of a Ru(II) Complex Catalyst and Ag Loading for Constructing a Highly Active Hybrid Photocatalyst Using C3N4 for CO2 Reduction

Synergetic Effect of Ligand Modification of a Ru(II) Complex Catalyst and Ag Loading for Constructing a Highly Active Hybrid Photocatalyst Using C₃N₄ for CO₂ Reduction

Ligand Modifications on a Cp(quinolate)Ru Catalyst to Improve Its Stability in a Bio-orthogonal Deprotection Reaction

Ligand Modifications on a Cp(quinolate)Ru Catalyst to Improve Its Stability in a Bio-orthogonal Deprotection Reaction

Polydentate Ligand Reinforced Chelating to Stabilize Buried Interface toward High-Performance Perovskite Solar Cells.

The instability of the buried interface poses a serious challenge for commercializing perovskite photovoltaic technology. Herein, we report a polydentate ligand reinforced chelating strategy to strengthen the stability of buried interface by managing interfacial defects and stress. The bis(2,2,2-trifluoroethyl) (methoxycarbonylmethyl)phosphonate (BTP) is employed to manipulate the buried interface. The C=O, P=O and two -CF3 functional groups in BTP synergistically passivate the defects from the surface of SnO2 and the bottom surface of the perovskite layer. Moreover, The BTP modification contributes to mitigated interfacial residual tensile stress, promoted perovskite crystallization, and reduced interfacial energy barrier. The multidentate ligand modulation strategy is appropriate for different perovskite compositions. Due to much reduced nonradiative recombination and heightened interface contact, the device with BTP yields a promising power conversion efficiency (PCE) of 24.63 %, which is one of the highest efficiencies ever reported for devices fabricated in the air environment. The unencapsulated BTP-modified devices degrade to 98.6 % and 84.2 % of their initial PCE values after over 3000 h of aging in the ambient environment and after 1728 h of thermal stress, respectively. This work provides insights into strengthening the stability of the buried interface by engineering multidentate chelating ligand molecules.

Polydentate Ligand Reinforced Chelating to Stabilize Buried Interface toward High‐Performance Perovskite Solar Cells

AbstractThe instability of the buried interface poses a serious challenge for commercializing perovskite photovoltaic technology. Herein, we report a polydentate ligand reinforced chelating strategy to strengthen the stability of buried interface by managing interfacial defects and stress. The bis(2,2,2‐trifluoroethyl) (methoxycarbonylmethyl)phosphonate (BTP) is employed to manipulate the buried interface. The C=O, P=O and two −CF3 functional groups in BTP synergistically passivate the defects from the surface of SnO2 and the bottom surface of the perovskite layer. Moreover, The BTP modification contributes to mitigated interfacial residual tensile stress, promoted perovskite crystallization, and reduced interfacial energy barrier. The multidentate ligand modulation strategy is appropriate for different perovskite compositions. Due to much reduced nonradiative recombination and heightened interface contact, the device with BTP yields a promising power conversion efficiency (PCE) of 24.63 %, which is one of the highest efficiencies ever reported for devices fabricated in the air environment. The unencapsulated BTP‐modified devices degrade to 98.6 % and 84.2 % of their initial PCE values after over 3000 h of aging in the ambient environment and after 1728 h of thermal stress, respectively. This work provides insights into strengthening the stability of the buried interface by engineering multidentate chelating ligand molecules.